

LARGEST
INFLUENZA
CONFERENCE
IN 2014



THE FIFTH ESWI
INFLUENZA
CONFERENCE

14-17 SEPTEMBER 2014 | RIGA

SECOND ANNOUNCEMENT

- Focus on novel data and current influenza threats
- Separate tailor-made programme for public health officials and opinion leaders in healthcare work
- Abstract submission until 15 May 2014
- Reduced rate for early bookings until 2 June 2014
- Travel and accommodation grants for young researchers
- Information and registration: www.eswiconference.org

Organized by
**European
Scientific
Working group on
Influenza**



THE FIFTH ESWI INFLUENZA CONFERENCE

14-17 SEPTEMBER 2014 | RIGA

The European Scientific Working group on Influenza (ESWI) is looking forward to organizing the fifth edition of its ESWI Influenza Conferences in Riga, Latvia, on 14 – 17 September 2014. Over the past 11 years, the ESWI Influenza Conferences have grown into the largest European scientific conferences entirely dedicated to influenza. In keeping with its excellent scientific reputation, the upcoming fifth edition will give the floor to the most renowned influenza scientists in order to showcase recent advances in basic science and the control and prevention of influenza, to stimulate the scientific debate on novel, unpublished research data and to advance our understanding of influenza by identifying new research routes. Additionally, the conference will have a second, tailor-made programme for public health officials and opinion leaders in healthcare work. They will be given the opportunity to participate in a series of seven sessions that cover the entire spectrum of influenza policy making.

SCIENTIFIC PROGRAMME COMMITTEE

ESWI's top level scientific programme committee, chaired by Prof. Ab Osterhaus, has direct access to all leading influenza scientists worldwide. The committee will have two vice-chairs: Prof. Peter Openshaw (Imperial College, London) will be co-responsible for the clinical quality of the programme, whilst Dr. Gülsah Gabriel (Heinrich-Pette-Institut, Hamburg) will coordinate the programme from a virological point of view. The combined expertise of the ESWI Board of Directors and the session chairs will form the conference's Scientific Advisory Board.

ESWI's unique position in the influenza field allows us to capitalize on the renewed interest in influenza control and prevention. Recent events, like the emergence of the H7N9 and H10N8 influenza viruses and the continued threat of H5N1, have emphasized the importance of improved preparedness. At the same time it is obvious that, in the years since the last ESWI conference, the influenza field has taken major steps forward: new analyses of flu vaccine effectiveness, the development of novel antiviral drugs and innovative influenza vaccines, the promise of a universal influenza vaccine... ESWI is in a perfect position to develop a state-of-art scientific programme that will appeal to all influenza-related disciplines.

SCIENTIFIC ADVISORY BOARD

- Ab Osterhaus, THE NETHERLANDS (CONFERENCE CHAIR)
- Gülsah Gabriel, GERMANY (CONFERENCE CO-CHAIR)
- Peter Openshaw, UK (CONFERENCE CO-CHAIR)
- Vincent Munster, USA (YOUNG SCIENTIST COMMITTEE CHAIR)
- Ted van Essen, THE NETHERLANDS
- Claude Hannoun, FRANCE
- Hans-Dieter Klenk, GERMANY
- Yoshihiro Kawaoka, JAPAN
- Juan Ortin, SPAIN
- Hualan Chen, PR CHINA
- Ron Fouchier, THE NETHERLANDS
- George Gao, PR CHINA
- Guus Rimmelzwaan, THE NETHERLANDS
- Derek Smith, UK
- Menno de Jong, THE NETHERLANDS
- Nancy Cox, USA
- Norio Sugaya, JAPAN
- Ian Brown, UK
- Peter Palese, USA
- Arnold Monto, USA
- David Salisbury, UK
- Abdullah Brooks, BANGLADESH
- Larissa Rudenko, RUSSIAN FEDERATION
- Jonathan Van-Tam, UK
- Marc Van Ranst, BELGIUM
- Colin Russell, UK
- Bruno Lina, FRANCE
- Terho Heikkinen, FINLAND
- Roman Prymula, CZECH REPUBLIC
- Meral Ciblak, TURKEY
- Sylvie Van der Werf, FRANCE
- Thomas Szucs, SWITZERLAND

SCIENTIFIC PROGRAMME

The Fifth ESWI Influenza Conference for **SCIENTISTS**

In keeping with its excellent scientific reputation, the Fifth ESWI Influenza Conference will give the floor to the most renowned influenza scientists and experts. Whatever your domain of expertise, the Fifth ESWI Influenza Conference is the premier conference bringing together professionals dedicated to all aspects of influenza.

All scientific sessions will be co-chaired by a young scientist, a token of ESWI's commitment to the future of the influenza field.

14 SEPTEMBER 2014

16:45-18:15 | SATELLITE SYMPOSIUM

Organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and ESWI

18:30-19:30 | OPENING CEREMONY

PLENARY ADDRESS:

- **Tonio Borg** European Commissioner Health and Consumer Policy

KEYNOTE ADDRESS:

A history of highly pathogenic avian influenza

- **Hans-Dieter Klenk** University of Marburg, Germany

19:30-22:00 | WELCOME RECEPTION

15 SEPTEMBER 2014

07:00-08:30 | BREAKFAST MEETING

Advancing the Influenza Research Agenda

- **Nahoko Shindo** World Health Organization
- **Irene Plank** DG Research & Innovation
- **Keith Klugman** Bill & Melinda Gates Foundation (tbc)

08:45-09:45 | PLENARY SESSION

KEYNOTE SPEECHES:

Influenza: cellular, molecular and pathogenic aspects of the virus

- **Yoshihiro Kawaoka** University of Tokyo, Japan

New emerging respiratory viruses. Where do we go?

- **Ab Osterhaus** Erasmus MC, The Netherlands

09:45-10:15 | COFFEE BREAK

GUIDED POSTER TOUR

10:15-12:00 | PARALLEL SESSIONS

Virus structure and replication

- CHAIR: **Juan Ortin** Centro Nacional de Biotecnología, Madrid, Spain
- CO-CHAIR: tbc

Clinical Impact and diagnostic approaches

- CHAIR: **Hualan Chen** Chinese Academy of Agricultural Sciences, Beijing, PR China
- CO-CHAIR: **Ken Baillie** University of Edinburgh, UK

12:00-14:00 | LUNCH

12:00-14:00 | SATELLITE SYMPOSIUM

Multiparty Group for Advice on Science (MUGAS) review and statistical analysis of oseltamivir data

14:00-15:45 | PARALLEL SESSIONS

Virus host interaction and pathogenesis

- CHAIR: **Ron Fouchier** Erasmus MC Rotterdam, The Netherlands
- CO-CHAIR: **Stephanie Bertram** University of Hamburg, Germany

Epidemics and pandemic threats

- CHAIR: **George Gao** Chinese Academy of Sciences, Beijing, PR China
- CO-CHAIR: **Jessica Belser** CDC, USA

15:45-16:15 | COFFEE BREAK

16:15-18:00 | PARALLEL SESSIONS

Immunology

- CHAIR: **Guus Rimmelzwaan** Erasmus MC Rotterdam, The Netherlands
- CO-CHAIR: **Christopher Brooke** NIH, USA

Mathematical modeling

- CHAIR: **Derek Smith** University of Cambridge, UK
- CO-CHAIR: **Chiara Poletto** INSERM, France

18:00-19:30 | SATELLITE SYMPOSIUM

Organized by the European Society for Paediatric Infectious Diseases (ESPID) and ESWI, Supported by AstraZeneca

16 SEPTEMBER 2014

07:30-08:30 | SATELLITE SYMPOSIUM

- Novavax: lecture title to be confirmed
- Medicago: "Update on the clinical development of plant-based influenza VLP vaccines"

08:45-09:45 | PLENARY SESSION

KEYNOTE SPEECHES:

Clinical management: current issues, new developments

- **Menno de Jong** University of Amsterdam, The Netherlands

Public policy and the politics of pandemics

- **Nancy Cox** Centers for Disease Control and Prevention, USA

09:45-10:15 | COFFEE BREAK

GUIDED POSTER TOUR

10:15-12:00	PARALLEL SESSIONS
Antivirals and resistance	
<ul style="list-style-type: none"> CHAIR: Norio Sugaya Keiyu Hospital, Yokohama, Japan CO-CHAIR: <i>tbc</i> 	
Animal flu-ecology and epidemiology of animal influenza	
<ul style="list-style-type: none"> CHAIR: Ian Brown Animal Health and Veterinary Laboratories Agency, UK CO-CHAIR: Ghazi Kayali St. Judes Childrens Hospital, USA 	
12:00-14:00	LUNCH
14:00-15:45	PARALLEL SESSIONS
Vaccines: current and novel approaches	
<ul style="list-style-type: none"> CHAIR: Ab Osterhaus Erasmus MC Rotterdam, The Netherlands CO-CHAIR: Natalie Pica Mount Sinai School of Medicine, USA 	
Genetics and evolution of virus and host	
<ul style="list-style-type: none"> CHAIR: Peter Palese Mount Sinai School of Medicine, USA CO-CHAIR: Debby van Riel Erasmus MC Rotterdam, The Netherlands 	
15:45-16:15	COFFEE BREAK
16:15-18:00	PARALLEL SESSIONS
Evaluation of vaccine safety and effectiveness	
<ul style="list-style-type: none"> CHAIR: Arnold Monto University of Michigan, USA CO-CHAIR: Saranya Sridhar Imperial College London, UK 	
Risk management and mitigation	
<ul style="list-style-type: none"> CHAIR: David Salisbury International Association of Immunization Managers CO-CHAIR: Jake Dunning Imperial College London, UK 	
18:00-19:30	SATELLITE SYMPOSIUM
Organized by FLURESP, the EU Health Programme project on the cost-effectiveness of European influenza pandemic alert and response strategies	
20:00-23:00	FAREWELL DINNER

17 SEPTEMBER 2014

08:45-09:45	PLENARY SESSION
ESWI Young Scientists Award Winners	
<ul style="list-style-type: none"> CHAIR: Vincent Munster Rocky Mountain Laboratories, Hamilton, USA CO-CHAIR: Claude Hannoun Institut Pasteur, France 	
09:45-10:15	COFFEE BREAK
	GUIDED POSTER TOUR
10:15-11:45	PARALLEL SESSIONS
Scientific approaches towards intervention strategies	
<ul style="list-style-type: none"> CHAIR: Peter Openshaw Imperial College London, UK CO-CHAIR: Erhard van der Vries Erasmus MC Rotterdam, The Netherlands 	
Maternal immunization	
<ul style="list-style-type: none"> CHAIR: Abdullah Brooks Infectious Diseases Unit at Kamalapur Field Site, Bangladesh CO-CHAIR: Florian Kramer, Mount Sinai School of Medicine, USA 	
11:45-13:15	LATE BREAKERS
<ul style="list-style-type: none"> CHAIR: Gülsah Gabriel Heinrich Pette Institute, Hamburg, Germany CO-CHAIR: Tokiko Watanabe University of Wisconsin-Madison, USA 	
13:15-13:30	CLOSING CEREMONY

The Fifth ESWI Influenza Conference for **PUBLIC HEALTH OFFICIALS** and **POLICY MAKERS**

Bridging the gap between science and health policy, that's the ultimate aim of the 'Science Policy Interface' (SPI), a separate programme track specifically dedicated to public health officials. In seven sessions, the world's leading experts will address the most intriguing health policy issues.

SESSION 1:

WHY SHOULD INFLUENZA BE A PUBLIC HEALTH PRIORITY?

Influenza is a moving target. It is a master in the art of metamorphosis, which makes the virus unpredictable. Yet there are numerous other reasons why influenza should be a public health priority, from the important scientific effort to spot emerging new flu strains and track their movement across the globe, to the sheer cost in human suffering and economic loss that the disease causes each year. However, one of the more difficult issues in public health policy is the matter of influenza vaccination for at-risk groups. Which segments of the population should receive priority for the administration of vaccines? This session provides the basics of influenza virology and reviews the scientific data that support vaccination recommendations for pregnant women, the elderly and the chronically ill.

SESSION 2:

INFLUENZA VACCINES: WHERE DO WE STAND? WHERE DO WE GO?

The annual flu vaccine offers the best protection against seasonal influenza. And when more people get vaccinated, less flu can spread through the community. Current flu vaccines work and are safe, but they cover only a select few strains of the virus and therefore have to be adapted and administered annually. But things are changing. This session explores the prospects of needle-free delivery, faster production cycles and broader protection. It also answers the question whether we are on the way towards a universal vaccine that protects against all types of (epidemic and pandemic) influenza.

SESSION 3:

INFLUENZA VACCINES REALLY WORK: TRUE OR FALSE?

In its last position paper, the World Health Organization states that pregnant women should be a priority group for influenza vaccination, next to the elderly, the chronically ill, children and healthcare workers. But European countries hold widely divergent policies regarding flu vaccination recommendations and vaccine uptake in the risk groups is often dramatically low. This session tackles some of the most persistent misconceptions about influenza vaccines and translates the newest scientific data on safety and effectiveness into daily policy practice.

SESSION 4:

HOW TO TREAT INFLUENZA: FOCUS ON ANTIVIRALS

Antiviral medicines are an essential tool to treat patients with an influenza infection, especially to reduce complications in at-risk groups. The stockpiling of antivirals is hence a pillar of any effective pandemic preparedness plan. There are compelling data that indicate that our current antiviral agents work well. In this context, the Programme Committee is very proud to announce the first results of a brand new study that has analyzed all available effectiveness data of oseltamivir, one of the most widely used antiviral agents against influenza. Still, it is fair to say that the number of effective antivirals is quite limited at the present time. And resistance of flu viruses to certain types of medicines is widespread. Luckily enough, there are a fair number of new promising products on the horizon. Current status and future prospects of influenza antivirals: all in one session.

SESSION 5:

WILL THERE EVER BE A NEW INFLUENZA PANDEMIC AND ARE WE PREPARED?

The sudden emergence of the H7N9 and H10N8 bird flu viruses in China illustrates the unpredictability of influenza. Will one of both spark the next influenza pandemic? What about the H5N1 flu virus that kills over 50% of its victims? It only needs a handful of mutations to become easily transmissible between humans, so why hasn't it caused a pandemic yet? And is Europe prepared to cope with a severe outbreak of pandemic influenza? This session gives a clear view on the issue of pandemic influenza, the challenges and caveats in Europe's preparedness plans and the link with an adequate response to the annual epidemics of seasonal influenza.

SESSION 6:

PUTTING FLU ON THE AGENDA OF SOCIETY

21st century healthcare needs 21st century thinking. Reaching vaccination targets requires the involvement of all stakeholders. The administration of vaccines at pharmacies, for instance, has the potential to further increase vaccine uptake. A central plank is the role of healthcare workers and how to persuade them to accept and promote influenza vaccination. What tools and methods exist for healthcare professionals to enhance communication with their patients and their peers? And what can governments do to improve the dialogue with the public in epidemic and pandemic periods? Can they get the right messages to people who are confronted with different opinions from different stakeholders?

SESSION 7:

CAN WE INFLUENCE PUBLIC PERCEPTION?

A major challenge to any influenza vaccination campaign is to assess risk perceptions about the disease. Understanding what drives people toward or away from vaccination is the first step to building an effective risk communication strategy. The impact of the press and the social media in this matter is ever-growing. Can we influence that conversation? Another issue surrounding influenza is to get a grip on its socio-economic burden. This session will weigh the benefits and the costs - whether direct, indirect or "avoided" to society - of influenza vaccination. All in the aim to see the information translated into health policy action that delivers positive results.

Programme at a glance

14 SEPTEMBER 2014	
16:45-18:15	SATELLITE SYMPOSIUM
<i>Organized by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and ESWI</i>	
18:30-19:30	OPENING CEREMONY
PLENARY ADDRESS:	
<ul style="list-style-type: none"> ▪ Tonio Borg <i>European Commissioner Health and Consumer Policy</i> 	
KEYNOTE ADDRESS:	
A history of highly pathogenic avian influenza <ul style="list-style-type: none"> ▪ Hans-Dieter Klenk <i>University of Marburg, Germany</i> 	
19:30-22:00	WELCOME RECEPTION

15 SEPTEMBER 2014	
07:00-08:30	BREAKFAST MEETING
Advancing the Influenza Research Agenda	
<ul style="list-style-type: none"> ▪ Nahoko Shindo <i>World Health Organization</i> ▪ Irene Plank <i>DG Research & Innovation</i> ▪ Keith Klugman <i>Bill & Melinda Gates Foundation (tbc)</i> 	
08:45-09:45	PLENARY SESSION
KEYNOTE SPEECHES:	
Influenza: cellular, molecular and pathogenic aspects of the virus <ul style="list-style-type: none"> ▪ Yoshihiro Kawaoka <i>University of Tokyo, Japan</i> 	
New emerging respiratory viruses. Where do we go? <ul style="list-style-type: none"> ▪ Ab Osterhaus <i>Erasmus MC, The Netherlands</i> 	
09:45-10:15	COFFEE BREAK
	GUIDED POSTER TOUR
10:15-12:00	Session 1: WHY SHOULD INFLUENZA BE A PUBLIC HEALTH PRIORITY?
The reality of influenza: a moving target! <ul style="list-style-type: none"> ▪ Ab Osterhaus <i>Erasmus MC Rotterdam, The Netherlands</i> 	
THE THREAT OF FLU IN RISK GROUPS:	
Protecting mother and child: <ul style="list-style-type: none"> ▪ Abdullah Brooks <i>Infectious Diseases Unit at Kamalapur Field Site, Bangladesh</i> 	
Protecting asthma and COPD patients (tbc)	
Protecting heart patients <ul style="list-style-type: none"> ▪ Raina McIntyre <i>University of New South Wales, Australia</i> 	
Protecting diabetes patients (tbc)	
Enhancing public engagement and communication about influenza <ul style="list-style-type: none"> ▪ Asiya Odugleh-Kolev <i>Team Leader, Behavioural and Social Interventions, WHO Geneva</i> 	

12:00-14:00	LUNCH
12:00-14:00	SATELLITE SYMPOSIUM
	Multiparty Group for Advice on Science (MUGAS) review and statistical analysis of oseltamivir data
14:00-15:45	Session 2: INFLUENZA VACCINES: WHERE DO WE STAND? WHERE DO WE GO?
Epidemic vaccines and (pre) pandemic vaccines – an overview	
<ul style="list-style-type: none"> ▪ Isabel Leroux-Roels <i>University Hospital Ghent, Belgium</i> 	
New generation of influenza vaccines	
<ul style="list-style-type: none"> ▪ Sarah Gilbert <i>Jenner Institute, Oxford University, UK</i> 	
Universal vaccination. On the road towards a vaccine that protects against all types of influenza?	
<ul style="list-style-type: none"> ▪ Guus Rimmelzwaan <i>Department of Viroscience, Erasmus MC Rotterdam, The Netherlands</i> 	
Closing the vaccination coverage gap: the 5A root cause audit	
<ul style="list-style-type: none"> ▪ Angus Thomson <i>Sanofi Pasteur, France</i> 	
15:45-16:15	COFFEE BREAK
16:15-18:00	Session 3: INFLUENZA VACCINES REALLY WORK: TRUE OR FALSE?
The Effectiveness Issue	
<ul style="list-style-type: none"> ▪ Jonathan Van-Tam <i>University of Nottingham, UK</i> 	
The Safety Issue	
<ul style="list-style-type: none"> ▪ Miriam Sturkenboom <i>Department of Medical Informatics, Erasmus MC Rotterdam, The Netherlands</i> 	
The reality of flu vaccine use in priority groups	
<ul style="list-style-type: none"> ▪ Caroline Brown <i>WHO Regional Office for Europe</i> 	
Nothing is 100% effective, nothing is 100% safe Communicating public health challenges	
<ul style="list-style-type: none"> ▪ John Parrish-Sprowl <i>Indiana University, USA</i> 	
18:00-19:30	SATELLITE SYMPOSIUM
<i>Organized by the European Society for Paediatric Infectious Diseases (ESPID) and ESWI, Supported by AstraZeneca</i>	

16 SEPTEMBER 2014	
07:30-08:30	SATELLITE SYMPOSIUM
<ul style="list-style-type: none"> ▪ <i>Novavax: lecture title to be confirmed</i> ▪ <i>Medicago: "Update on the clinical development of plant-based influenza VLP vaccines"</i> 	

08:45-09:45	PLENARY SESSION
KEYNOTE SPEECHES:	
Clinical management: current issues, new developments	
▪ Menno de Jong <i>University of Amsterdam, The Netherlands</i>	
Public policy and the politics of pandemics	
▪ Nancy Cox <i>Centers for Disease Control and Prevention, USA</i>	
09:45-10:15	COFFEE BREAK
	GUIDED POSTER TOUR
10:15-12:00	Session 4: HOW TO TREAT INFLUENZA: FOCUS ON ANTIVIRALS
Deploying antiviral agents against seasonal influenza	
▪ Ted van Essen <i>University Medical Center, Utrecht, The Netherlands</i>	
Deploying antiviral agents against pandemic influenza	
▪ Peter Openshaw <i>Imperial College London, UK</i>	
MUGAS review and statistical analysis of oseltamivir data: the outcome.	
▪ Rich Whitley <i>University of Alabama at Birmingham, USA</i>	
The future of influenza antivirals	
▪ Erhard van der Vries <i>Department of Viroscience, Erasmus MC Rotterdam, The Netherlands</i>	
12:00-14:00	LUNCH
14:00-15:45	Session 5: WILL THERE EVER BE A NEW INFLUENZA PANDEMIC AND ARE WE PREPARED?
Seasonal flu preparedness leads to better pandemic preparedness	
▪ Chloe Sellwood <i>Pandemic Flu Lead NHS, UK</i>	
The history of flu pandemics and the threat of H5N1	
▪ Colin Russell <i>Cambridge University, UK</i>	
H7N9 and other looming flu threats	
▪ Sander Herfst <i>Department of Viroscience, Erasmus MC Rotterdam, The Netherlands</i>	
Lethal viruses travel tricky routes	
▪ Yoshihiro Kawaoka <i>University of Tokyo, Japan</i>	
15:45-16:15	COFFEE BREAK
16:15-18:00	Session 6: PUTTING FLU ON THE AGENDA OF SOCIETY
The role of pharmacists in vaccination strategies	
▪ Rute Horta <i>National Association of Pharmacies, Portugal</i>	
Talking protection with patients: equipping HCPs with tools and methods	
▪ Eugenijus Laurinaitis <i>Dept. of Psychiatry, Vilnius University, Lithuania</i>	
Communicating flu to all stakeholders: the experience of the Belgian commissioner on flu	
▪ Marc Van Ranst <i>University of Leuven, Belgium</i>	
Why should governments and public health foundations care about influenza?	
▪ Keith Klugman <i>director Pneumonia programme B&M Gates Foundation</i>	
18:00-19:30	SATELLITE SYMPOSIUM
<i>Organized by FLURESP, the EU Health Programme project on the cost-effectiveness of European influenza pandemic alert and response strategies</i>	
20:00-23:00	FAREWELL DINNER

17 SEPTEMBER 2014

08:45-09:45	PLENARY SESSION
Focus on the work of promising Young Scientists in the field of influenza	
09:45-10:15	COFFEE BREAK
	GUIDED POSTER TOUR

10:15-11:45	Session 7: CAN WE INFLUENCE PUBLIC PERCEPTION?
Risk perception and communication in vaccination decisions: a fuzzy-trace theory approach	
▪ Noel Brewer <i>University of North Carolina, USA</i>	
Talking about health issues to journalists	
▪ Debra McKenzie <i>New Scientist Magazine</i>	
The economic and social benefits of flu prevention	
▪ Mark Jit <i>Public Health England, UK</i>	
What is society saying about flu in the social media space: can we influence the conversation?	
▪ Stéphane Suisse <i>Social Engineer, Sanofi Pasteur</i>	
11:45-13:15	LATE BREAKERS
▪ CHAIR: Gülsah Gabriel <i>Heinrich Pette Institute, Hamburg, Germany</i>	
▪ CO-CHAIR: Tokiko Watanabe <i>University of Wisconsin-Madison, USA</i>	
13:15-13:30	CLOSING CEREMONY
13:30-14:30	LUNCH

SCIENCE POLICY INTERFACE 2.0: THE REFLECTION TEAMS

To further enhance the interaction, ESWI introduces the Reflection Team, i.e. a team of commenters, who will reflect on the session's content and Q&A from their expertise and knowledge. Reflection Teams will be differently composed every session and may include public health officials, healthcare professionals, scientific experts from a different domain, journalists...

IMPORTANT NOTICE

All conference delegates are free to attend the sessions of their choice. Public Health Officials are hence very welcome to join other delegates at satellite symposia, breakfast meetings, conference dinners and scientific sessions. After all, all plenary sessions and social events are an integral part of the Science Policy Interface programme.

A separate brochure on the concept and content of the Science Policy Interface is available for download at www.eswiconference.org.

Young Scientist Fund ESWI



Since some of the best and most innovative ideas come from young scientists, ESWI actively encourages the careers of young researchers, contributing to Europe's continued leading scientific base in influenza research. Through the Young Scientist Fund, ESWI provides some 50 grants to young scientists. Candidates can be awarded a travel and accommodation grant of €850 (EU residents) or €1,250 (non-EU residents) if they submit their online grant application before 15 May 2014. Check the Young Scientist section on the conference website for all information.



Additional conference support is made available by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) for ESCMID young scientist members.

Information is available at www.escmid.org.

Invited young scientists will act as co-chairs during the conference sessions, and Wednesday 17 September 2014 will open with a plenary session entirely devoted to the work of promising scientists. In past editions, these plenaries were highly appreciated in the influenza community, mainly due to their innovative and refreshing nature.

Call for **abstracts**

ESWI encourages work that introduces new ideas and conceptualizations, research and understandings to the field. The call for abstracts is limited to the scientific sessions only. A list of topics is to be found on this page and on the conference website.

- Abstracts can only be submitted online via the conference website; submissions by fax, post or email will not be considered.
- Submission deadline is **15 May 2014**. Kindly follow the instructions on the abstract submission page.
- Accepted abstracts will be allocated to the appropriate scientific session. Notification of acceptance and instructions for oral or poster presentations will be sent by **1 June 2014** via e-mail.
- Presenting authors who are accepted must register and pay conference registration fees. Registration fees not received will result in the withdrawal of the abstract.



Posters

Posters sessions are included in the conference programme:

TOUR 1: MONDAY 15 SEPTEMBER 2014 (09:45-10:15)

Prof. Ab Osterhaus on the following topics:

- Virus structure and replication
- Clinical Impact and diagnostic approaches
- Virus host interaction and pathogenesis
- Epidemics and pandemic threats
- Immunology
- Mathematical modeling

TOUR 2: TUESDAY 16 SEPTEMBER 2014 (09:45-10:15)

Prof. Peter Openshaw on the following topics:

- Antivirals and resistance
- Animal flu-ecology and epidemiology of animal influenza
- Vaccines: current and novel approaches
- Genetics and evolution of virus and host
- Evaluation of vaccine safety and effectiveness
- Risk management and mitigation

TOUR 3: WEDNESDAY 17 SEPTEMBER 2014 (09:45-10:15)

Dr. Gülsah Gabriel on the following topics:

- Maternal immunization
- Scientific approaches towards intervention strategies
- Late Breakers

Publication

All abstracts (oral and poster presentations) will be published in the conference programme book as well as on the conference website.

TOPICS

- Virus structure and replication
- Clinical Impact and diagnostic approaches
- Virus host interaction and pathogenesis
- Epidemics and pandemic threats
- Immunology
- Mathematical modeling
- Antivirals and resistance
- Animal flu-ecology and epidemiology of animal influenza
- Vaccines: current and novel approaches
- Genetics and evolution of virus and host
- Evaluation of vaccine safety and effectiveness
- Risk management and mitigation
- Maternal immunization
- Scientific approaches towards intervention strategies
- Late Breakers

▾ THE CITY

The Fifth ESWI Influenza Conference will take you to Riga, capital of Latvia. Riga is home to around 700,000 inhabitants, making it an ideally sized city for a successful and attractive conference. The most ancient part of the town is a unique cultural treasure now recognised by UNESCO as a World Heritage Site. Building a bridge between the Eastern and the Western parts of Europe, Riga is attracting a growing number of business visitors and it is hence the perfect venue for the 2014 ESWI Influenza Conference.


▾ THE VENUE

The Fifth ESWI Influenza Conference will take place at the Radisson Blu Hotel Latvija in Riga. Accommodation for the conference is not included in the registration fee and should hence be booked separately.

The accommodation booking tool on www.eswicongference.org allows you to browse through a list of preferred hotels and to book & pay your hotel room in just a few clicks.

▾ CONFERENCE LANGUAGE

The official language of the Fifth ESWI Influenza Conference will be English.



Registration Fees

	Early <i>(until 2 June 2014)</i>	Full
DELEGATE	€ 850.00	€ 1,050.00
YOUNG SCIENTIST	€ 850.00	€ 850.00
EXHIBITOR	€ 350.00	€ 450.00
Dinner voucher for accompanying persons*	€ 85	€ 85

* Voucher includes Welcome Buffet and Farewell Dinner / make your reservation via the online registration system


WHAT IS INCLUDED IN THE REGISTRATION RATE?

- Airport Transfer
- Opening Ceremony on 14 September 2014
- Welcome Reception on 14 September 2014
- Access to all Conference Sessions (except for exhibitors)
- Coffee Break - Refreshments
- Conference Lunches
- Farewell Dinner on 16 September 2014

▶ SUPPORTING PARTNERS



These institutions and companies have provided funding to the Fifth ESWI Influenza Conference. None of them had any input into the content of the materials and presentations used at this event.



▶ OFFICIAL CARRIER



Lufthansa is the official carrier of the Fifth ESWI Influenza Conference. All conference delegates benefit from a 5 to 10% discount on published rates for travel on Lufthansa scheduled services. Detailed information is available at www.eswiconference.org.

Information and registration:
www.eswiconference.org

If you have any questions
about the Fifth ESWI Influenza
Conference, please contact:
DAVID DE POOTER
ESWI management
e-mail: david.depooter@eswi.org
mobile: +32 479 45 74 46

ABOUT ESWI

The European Scientific Working group on Influenza (ESWI) is a network of independent influenza experts and organizations of public health officials, healthcare professionals, at-risk patients and the elderly. Together, we aim to reduce the burden of influenza in Europe.

- More info about ESWI is to be found on **www.eswi.org**
- Register to our closed community for Public Health Officials at **www.flucommunity.org**
- Check our online influenza knowledge centre at **www.flucentre.net**
- Join us on Facebook: **www.facebook.com/EuropeanScientistsFightingInfluenza**



Follow the latest conference updates on Twitter: @ESWIRigaConfere